Major shareholder notification
In accordance with Section 29 of the Securities Trading Act, Novo
Nordisk hereby reports that on 4 November 2008 Novo Nordisk received
notification from The Capital Group Companies Inc. that it pursuant
to letter of application of 7 February 2008 to the Danish FSA
regarding the exemption requirements for parent companies under
Executive Order 1225 section 12 and 14 no longer will report interest
in securities in Denmark on its own behalf. Instead, voting interest
and ownership in shares will be reported separately by Capital
Research and Management Company, Capital Group International Inc. or
the mutual funds and clients themselves, as appropriate. None of the
individual entities have shareholdings above the threshold of 5% of
the issued share capital.
Further, The Capital Group Companies Inc. informed Novo Nordisk that
the filing is not being made to reflect an acquisition or disposition
of shares, but rather to reflect that the Capital Group Companies
Inc. as a parent company is exempted from the requirements to file
aggregate ownership reports under Executive Order 1225. Should the
voting interests or ownership in shares held by Capital Research and
Management Company, Capital Group International Inc. or the mutual
funds and clients exceed a reporting threshold, such entity will file
a report separately in the future.
Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 26,550
employees in 80 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.
Further information:
Media: Investors:
Elin K Hansen Mads Veggerby Lausten
Tel (direct): (+45) 4442 3450 Tel (direct): (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
Hans Rommer
Tel (direct): (+45) 4442 4765
hrmm@novonordisk.com
In North America:
Sean Clements Kasper Roseeuw Poulsen
Tel (direct): (+1) 609 514 8316 Tel (direct): (+45) 4442 4471
secl@novonordisk.com krop@novonordisk.com
Company Announcement no 73 / 2008
